psilocybin / Braxia Scientific - LARVOL DELTA

Cognitive outcomes following psilocybin-assisted therapy in treatment-resistant depression: A post-hoc analysis of a randomized, waitlist-controlled trial. (PubMed, Prog Neuropsychopharmacol Biol Psychiatry) - "PAP was associated with modest, short-term improvements in performance on measures of processing speed and executive function among individuals with TRD. While these changes appeared independent of mood, they did not consistently exceed expected practice effects. These findings highlight the need for adequately powered, controlled trials to clarify whether observed cognitive changes reflect genuine procognitive effects of psilocybin or are attributable to non-specific influences such as test familiarity or concurrent mood improvements."

Journal • Retrospective data • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry • Suicidal Ideation

Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression in Bipolar II Disorder. (PubMed, Psychedelic Med (New Rochelle)) - "These findings suggest potential improvement in depressive symptoms with psilocybin administration in BD-II. Future studies with larger sample size are required to replicate our results and further evaluate antidepressant effects of psilocybin in bipolar depression."

Journal • Bipolar Disorder • CNS Disorders • Depression • Mood Disorders • Psychiatry

Psilocybin-assisted psychotherapy for treatment resistant depression: A randomized clinical trial evaluating repeated doses of psilocybin. (PubMed, Med) - P2 | "PAP was feasible in complex patients with preliminary antidepressant efficacy and adequate safety and tolerability. Repeated doses were associated with greater reductions in depression severity."

Clinical • Journal • Bipolar Disorder • Borderline Personality Disorder • CNS Disorders • Cognitive Disorders • Depression • Major Depressive Disorder • Mood Disorders • Personality Disorder • Psychiatry

Psilocybin for Treatment-Resistant Depression (clinicaltrials.gov) - P2 | N=30 | Completed | Sponsor: Brain and Cognition Discovery Foundation | Active, not recruiting ➔ Completed | Trial completion date: Feb 2023 ➔ Jul 2023 | Trial primary completion date: Feb 2023 ➔ Jul 2023

Trial completion • Trial completion date • Trial primary completion date • CNS Disorders • Depression • Mood Disorders • Psychiatry • BDNF • IL6

Psilocybin for Treatment-Resistant Depression (clinicaltrials.gov) - P2 | N=30 | Active, not recruiting | Sponsor: Brain and Cognition Discovery Foundation | Recruiting ➔ Active, not recruiting

Enrollment closed • CNS Disorders • Depression • Mood Disorders • Psychiatry • BDNF • IL6

Psilocybin for Treatment-Resistant Depression (clinicaltrials.gov) - P2; N=30; Recruiting; Sponsor: Brain and Cognition Discovery Foundation; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • CNS Disorders • Depression • Mood Disorders • Psychiatry • BDNF • IL6

Psilocybin for Treatment-Resistant Depression (clinicaltrials.gov) - P2; N=30; Not yet recruiting; Sponsor: Brain and Cognition Discovery Foundation

Clinical • New P2 trial • CNS Disorders • Depression • Mood Disorders • Psychiatry • IL6

Braxia Scientific to Commence Landmark Clinical Trial to Conduct Canada’s First Multiple-Dose Psilocybin Clinical Trial for Treatment Resistant Depression (PRNewswire) - "Trial will include adults with treatment-resistant depression and will also enroll adults who have previously tried electroconvulsive therapy and/or intravenous ketamine....Braxia Scientific Corp....is pleased to announce Braxia Scientific's clinical research and development team will commence a randomized clinical trial (RCT) using psilocybin....This will enable the Company...providing the opportunity to evaluate the therapist training program launched at the end of June 2021. This program run by the Braxia Institute, the Company's training centre focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy..."

Trial status • CNS Disorders • Depression